The key-stone in the diagnostics of postmenopausal osteoporosis in most countries world-wide is the measurement of bone mineral density (BMD). The laboratory investigation is supportive, especially in secondary osteoporosis.
Therapy is covered by Czech health insurance companies in cases with BMD under -2.5 T-score, only. In the USA much more interest is focused on patients with osteopenia and preventive dosing of bisphosphonates is supported